Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

»ç¶÷ÀÇ ³­¼Ò »óÇÇÁ¾¾ç ¼¼Æ÷ÁÖ¿¡¼­ All-trans-retinoic AcidÀÇ Ç×¾Ï È¿°ú¿Í Apoptosis¿ÍÀÇ ¿¬°ü¼º Anticancer Effect and Apoptosis of All-trans-retinoic Acid on the Human Ovarian Epithelial Carcinoma Cell Lines

´ëÇѺ´¸®ÇÐȸÁö 2000³â 34±Ç 3È£ p.225 ~ 234
ÇÑÁö¿µ, Á¤¿ìÈñ, ±èŽÂ,
¼Ò¼Ó »ó¼¼Á¤º¸
ÇÑÁö¿µ ( Han Jee-Young ) 
ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

Á¤¿ìÈñ ( Jung Woo-Hee ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
±èŽ ( Kim Tai-Seung ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

Abstract


Ovarian carcinoma is a serious disease in women. Some reports revealed all-trans-retinoic acid (tRA) inhibited the proliferation of ovarian carcinoma cell lines and induced apoptosis. The aim of this study was to evaluate the anticancer and apoptotic effects of tRA and the expression of the retinoic acid receptor (RAR) ¥á, ¥â, ¥ã, p53, bcl-2, and c-myc genes on the ovarian carcinoma cell lines, NIH OVCAR3 and SKOV3. In both cell lines, the proliferation of tumor cells was inhibited and characteristic morphologic patterns of apoptosis were shown after treatment of tRA. The number of apoptotic cells and the percentage of apoptosis were increased after treatment of tRA. The gel electrophoresis revealed the DNA ladder pattern in the NIH OVCAR3. Gene expressions were observed using northern blotting. There was no RAR¥á expression in both cell lines. In NIH OVCAR3, there was no changes in the expression of RAR¥â and bcl-2 gene. The RAR¥ã gene expression of tRA treated group was slightly increased, but p53 gene expression was decreased, and c-myc gene was not expressed. In SKOV3, the expressions of RAR¥â, ¥ã, and p53 genes were increased and that of bcl-2 was decreased in the tRA treated group. There was no change in c-myc gene expression. These results suggest tRA has anticancer and apoptotic effect on both ovarian carcinoma cell lines. RAR¥â, RAR¥ã, bcl-2, and p53 gene expressions were correlated with these effects of tRA on SKOV3 but not on NIH OVCAR3.

Å°¿öµå

Ovarian carcinoma;tRNA;Anticancer effect;Apoptosis

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS